Phio raises ~$2M in registered direct offering with warrants, amends existing warrants

Phio Pharmaceuticals Corp.

Issued 353,983 shares at $5.65/share, gross proceeds ~$2.0M; net ~$1.65M after fees.
Concurrent private placement: Series A (5.5-yr) and Series B (18-mo) warrants for up to 707,966 shares at $5.40.
Amended 191,619 existing warrants from exercise prices $26.52–$2,079.00 down to $5.40 for $0.125 each.
Net proceeds for immuno-oncology development, working capital, and general corporate purposes.
Offering closed April 20, 2023; H.C. Wainwright acted as exclusive placement agent.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Phio Pharmaceuticals Corp. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-01-20).

Action: entry
Agreement: underwriting
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2023-01-20

Exact text from the filing

Pursuant to an engagement letter, dated as of January 20, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC, or the placement agent

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Phio Pharmaceuticals Corp. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.65 million (effective 2023-04-18).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $1.65 million
Effective: 2023-04-18

Exact text from the filing

On April 18, 2023, Phio Pharmaceuticals Corp. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 353,983 shares of the Company’s common stock

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-23-002542

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.